-
Je něco špatně v tomto záznamu ?
Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer
LW. de Boo, K. Jóźwiak, ND. Ter Hoeve, PJ. van Diest, M. Opdam, Y. Wang, MK. Schmidt, V. de Jong, S. Kleiterp, S. Cornelissen, D. Baars, RHT. Koornstra, ED. Kerver, T. van Dalen, AD. Bins, A. Beeker, SM. van den Heiligenberg, PC. de Jong, SD....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2016
PubMed Central
od 2016
Europe PubMed Central
od 2016
Open Access Digital Library
od 2016-01-01
Elsevier Open Access Journals
od 2016
ROAD: Directory of Open Access Scholarly Resources
od 2016
- MeSH
- adjuvantní chemoterapie MeSH
- lidé MeSH
- nádorové biomarkery MeSH
- prognóza MeSH
- triple-negativní karcinom prsu * farmakoterapie patologie MeSH
- tumor infiltrující lymfocyty metabolismus patologie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: In the absence of prognostic biomarkers, most patients with early-stage triple-negative breast cancer (eTNBC) are treated with combination chemotherapy. The identification of biomarkers to select patients for whom treatment de-escalation or escalation could be considered remains an unmet need. We evaluated the prognostic value of histopathologic traits in a unique cohort of young, (neo)adjuvant chemotherapy-naïve patients with early-stage (stage I or II), node-negative TNBC and long-term follow-up, in relation to stromal tumor-infiltrating lymphocytes (sTILs) for which the prognostic value was recently reported. MATERIALS AND METHODS: We studied all 485 patients with node-negative eTNBC from the population-based PARADIGM cohort which selected women aged <40 years diagnosed between 1989 and 2000. None of the patients had received (neo)adjuvant chemotherapy according to standard practice at the time. Associations between histopathologic traits and breast cancer-specific survival (BCSS) were analyzed with Cox proportional hazard models. RESULTS: With a median follow-up of 20.0 years, an independent prognostic value for BCSS was observed for lymphovascular invasion (LVI) [adjusted (adj.) hazard ratio (HR) 2.35, 95% confidence interval (CI) 1.49-3.69], fibrotic focus (adj. HR 1.61, 95% CI 1.09-2.37) and sTILs (per 10% increment adj. HR 0.75, 95% CI 0.69-0.82). In the sTILs <30% subgroup, the presence of LVI resulted in a higher cumulative incidence of breast cancer death (at 20 years, 58%; 95% CI 41% to 72%) compared with when LVI was absent (at 20 years, 32%; 95% CI 26% to 39%). In the ≥75% sTILs subgroup, the presence of LVI might be associated with poor survival (HR 11.45, 95% CI 0.71-182.36, two deaths). We confirm the lack of prognostic value of androgen receptor expression and human epidermal growth factor receptor 2 -low status. CONCLUSIONS: sTILs, LVI and fibrotic focus provide independent prognostic information in young women with node-negative eTNBC. Our results are of importance for the selection of patients for de-escalation and escalation trials.
Cancer Center University Medical Center Utrecht Utrecht The Netherlands
Candiolo Cancer Institute FPO IRCCS Candiolo Italy
Charles University Medical Faculty and University Hospital Hradec Kralove Czech Republic
Department of Biometrics The Netherlands Cancer Institute Amsterdam The Netherlands
Department of Clinical Genetics Leiden University Medical Centre Leiden The Netherlands
Department of Epidemiology Maastricht University Maastricht The Netherlands
Department of Internal Medicine Deventer Hospital Deventer The Netherlands
Department of Internal Medicine Zaans Medical Centre Zaandam The Netherlands
Department of Medical Oncology Amsterdam UMC Amsterdam The Netherlands
Department of Medical Oncology Amsterdam UMC Cancer Center Amsterdam Amsterdam The Netherlands
Department of Medical Oncology Dijklander Ziekenhuis Hoorn The Netherlands
Department of Medical Oncology OLVG Amsterdam The Netherlands
Department of Medical Oncology Rijnstate Medical center Arnhem The Netherlands
Department of Medical Oncology Rode Kruis Hospital Beverwijk The Netherlands
Department of Medical Oncology Saxenburgh Medical Center Hardenberg The Netherlands
Department of Medical Oncology Sint Antonius Hospital Utrecht The Netherlands
Department of Medical Oncology Spaarne Gasthuis Hoofddorp The Netherlands
Department of Medical Oncology The Netherlands Cancer Institute Amsterdam The Netherlands
Department of Medical Oncology UMC Utrecht Cancer Center Utrecht The Netherlands
Department of Medical Sciences University of Torino Torino Italy
Department of Molecular Pathology the Netherlands Cancer Institute Amsterdam The Netherlands
Department of Pathology and Molecular Pathology University Hospital Zurich Zurich Switzerland
Department of Pathology Canisius Wilhelmina Ziekenhuis Nijmegen The Netherlands
Department of Pathology Complejo Hospitalaria de Navarra Pamplona Spain
Department of Pathology Erasmus University Medical Center Rotterdam Rotterdam The Netherlands
Department of Pathology Gelre Ziekenhuizen Apeldoorn The Netherlands
Department of Pathology GZA ZNA Hospitals Antwerp Belgium
Department of Pathology Leiden University Medical Center Leiden The Netherlands
Department of Pathology Netherlands Cancer Institute Amsterdam The Netherlands
Department of Pathology Rion University Hospital Patras Greece
Department of Pathology University Medical Center Utrecht Utrecht The Netherlands
Department of Surgery Diakonessenhuis Utrecht Utrecht The Netherlands
Department of Tumorbiology and Immunology The Netherlands Cancer Institute Amsterdam The Netherlands
Division of Clinical Medicine and Research Peter MacCallum Cancer Centre Melbourne Australia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006831
- 003
- CZ-PrNML
- 005
- 20240423155522.0
- 007
- ta
- 008
- 240412s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.esmoop.2024.102923 $2 doi
- 035 __
- $a (PubMed)38452438
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a de Boo, L W $u Department of Molecular Pathology, the Netherlands Cancer Institute, Amsterdam, The Netherlands
- 245 10
- $a Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer / $c LW. de Boo, K. Jóźwiak, ND. Ter Hoeve, PJ. van Diest, M. Opdam, Y. Wang, MK. Schmidt, V. de Jong, S. Kleiterp, S. Cornelissen, D. Baars, RHT. Koornstra, ED. Kerver, T. van Dalen, AD. Bins, A. Beeker, SM. van den Heiligenberg, PC. de Jong, SD. Bakker, RC. Rietbroek, IR. Konings, R. Blankenburgh, RM. Bijlsma, ALT. Imholz, N. Stathonikos, W. Vreuls, J. Sanders, EH. Rosenberg, EA. Koop, Z. Varga, CHM. van Deurzen, AL. Mooyaart, A. Córdoba, E. Groen, J. Bart, SM. Willems, V. Zolota, J. Wesseling, A. Sapino, E. Chmielik, A. Ryska, A. Broeks, AC. Voogd, E. van der Wall, S. Siesling, R. Salgado, GMHE. Dackus, M. Hauptmann, M. Kok, SC. Linn
- 520 9_
- $a BACKGROUND: In the absence of prognostic biomarkers, most patients with early-stage triple-negative breast cancer (eTNBC) are treated with combination chemotherapy. The identification of biomarkers to select patients for whom treatment de-escalation or escalation could be considered remains an unmet need. We evaluated the prognostic value of histopathologic traits in a unique cohort of young, (neo)adjuvant chemotherapy-naïve patients with early-stage (stage I or II), node-negative TNBC and long-term follow-up, in relation to stromal tumor-infiltrating lymphocytes (sTILs) for which the prognostic value was recently reported. MATERIALS AND METHODS: We studied all 485 patients with node-negative eTNBC from the population-based PARADIGM cohort which selected women aged <40 years diagnosed between 1989 and 2000. None of the patients had received (neo)adjuvant chemotherapy according to standard practice at the time. Associations between histopathologic traits and breast cancer-specific survival (BCSS) were analyzed with Cox proportional hazard models. RESULTS: With a median follow-up of 20.0 years, an independent prognostic value for BCSS was observed for lymphovascular invasion (LVI) [adjusted (adj.) hazard ratio (HR) 2.35, 95% confidence interval (CI) 1.49-3.69], fibrotic focus (adj. HR 1.61, 95% CI 1.09-2.37) and sTILs (per 10% increment adj. HR 0.75, 95% CI 0.69-0.82). In the sTILs <30% subgroup, the presence of LVI resulted in a higher cumulative incidence of breast cancer death (at 20 years, 58%; 95% CI 41% to 72%) compared with when LVI was absent (at 20 years, 32%; 95% CI 26% to 39%). In the ≥75% sTILs subgroup, the presence of LVI might be associated with poor survival (HR 11.45, 95% CI 0.71-182.36, two deaths). We confirm the lack of prognostic value of androgen receptor expression and human epidermal growth factor receptor 2 -low status. CONCLUSIONS: sTILs, LVI and fibrotic focus provide independent prognostic information in young women with node-negative eTNBC. Our results are of importance for the selection of patients for de-escalation and escalation trials.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a prognóza $7 D011379
- 650 12
- $a triple-negativní karcinom prsu $x farmakoterapie $x patologie $7 D064726
- 650 _2
- $a tumor infiltrující lymfocyty $x metabolismus $x patologie $7 D016246
- 650 _2
- $a nádorové biomarkery $7 D014408
- 650 _2
- $a adjuvantní chemoterapie $7 D017024
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Jóźwiak, K $u Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany
- 700 1_
- $a Ter Hoeve, N D $u Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
- 700 1_
- $a van Diest, P J $u Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
- 700 1_
- $a Opdam, M $u Department of Molecular Pathology, the Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Wang, Y $u Department of Molecular Pathology, the Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Schmidt, M K $u Department of Molecular Pathology, the Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands
- 700 1_
- $a de Jong, V $u Department of Molecular Pathology, the Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Kleiterp, S $u Department of Molecular Pathology, the Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Cornelissen, S $u Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Baars, D $u Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Koornstra, R H T $u Department of Medical Oncology, Rijnstate Medical center, Arnhem, The Netherlands
- 700 1_
- $a Kerver, E D $u Department of Medical Oncology, OLVG, Amsterdam, The Netherlands
- 700 1_
- $a van Dalen, T $u Department of Surgery, Diakonessenhuis Utrecht, Utrecht, The Netherlands
- 700 1_
- $a Bins, A D $u Department of Medical Oncology, Amsterdam UMC, Amsterdam, The Netherlands
- 700 1_
- $a Beeker, A $u Department of Medical Oncology, Spaarne Gasthuis, Hoofddorp, The Netherlands
- 700 1_
- $a van den Heiligenberg, S M $u Department of Medical Oncology, Dijklander Ziekenhuis, Hoorn, The Netherlands
- 700 1_
- $a de Jong, P C $u Department of Medical Oncology, Sint Antonius Hospital, Utrecht, The Netherlands
- 700 1_
- $a Bakker, S D $u Department of Internal Medicine, Zaans Medical Centre, Zaandam, The Netherlands
- 700 1_
- $a Rietbroek, R C $u Department of Medical Oncology, Rode Kruis Hospital, Beverwijk, The Netherlands
- 700 1_
- $a Konings, I R $u Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, The Netherlands
- 700 1_
- $a Blankenburgh, R $u Department of Medical Oncology, Saxenburgh Medical Center, Hardenberg, The Netherlands
- 700 1_
- $a Bijlsma, R M $u Department of Medical Oncology, UMC Utrecht Cancer Center, Utrecht, The Netherlands
- 700 1_
- $a Imholz, A L T $u Department of Internal Medicine, Deventer Hospital, Deventer, The Netherlands
- 700 1_
- $a Stathonikos, N $u Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
- 700 1_
- $a Vreuls, W $u Department of Pathology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands
- 700 1_
- $a Sanders, J $u Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Rosenberg, E H $u Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Koop, E A $u Department of Pathology, Gelre Ziekenhuizen, Apeldoorn, The Netherlands
- 700 1_
- $a Varga, Z $u Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
- 700 1_
- $a van Deurzen, C H M $u Department of Pathology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
- 700 1_
- $a Mooyaart, A L $u Department of Pathology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
- 700 1_
- $a Córdoba, A $u Department of Pathology, Complejo Hospitalaria de Navarra, Pamplona, Spain
- 700 1_
- $a Groen, E $u Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Bart, J $u Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands
- 700 1_
- $a Willems, S M $u Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands
- 700 1_
- $a Zolota, V $u Department of Pathology, Rion University Hospital, Patras, Greece
- 700 1_
- $a Wesseling, J $u Department of Molecular Pathology, the Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
- 700 1_
- $a Sapino, A $u Department of Medical Sciences, University of Torino, Torino, Italy; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
- 700 1_
- $a Chmielik, E $u Tumor Pathology Department, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Gliwice, Poland
- 700 1_
- $a Ryska, A $u Charles University Medical Faculty and University Hospital, Hradec Kralove, Czech Republic
- 700 1_
- $a Broeks, A $u Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Voogd, A C $u Department of Epidemiology, Maastricht University, Maastricht, The Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands
- 700 1_
- $a van der Wall, E $u Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands
- 700 1_
- $a Siesling, S $u Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands; Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands
- 700 1_
- $a Salgado, R $u Division of Clinical Medicine and Research, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium
- 700 1_
- $a Dackus, G M H E $u Department of Molecular Pathology, the Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
- 700 1_
- $a Hauptmann, M $u Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany
- 700 1_
- $a Kok, M $u Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Tumorbiology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Linn, S C $u Department of Molecular Pathology, the Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: s.linn@nki.nl
- 773 0_
- $w MED00196632 $t ESMO open $x 2059-7029 $g Roč. 9, č. 3 (2024), s. 102923
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38452438 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155519 $b ABA008
- 999 __
- $a ok $b bmc $g 2081044 $s 1216598
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 9 $c 3 $d 102923 $e 20240306 $i 2059-7029 $m ESMO open $n ESMO Open $x MED00196632
- LZP __
- $a Pubmed-20240412
